Johnson & Johnson reported fourth-quarter adjusted earnings per share of $2.45, outpacing consensus by $0.08, while revenues rose 5.8% year-on-year to $25.1 billion, beating forecasts by $400 million. Pharmaceutical sales grew 7.2%, driven by oncology franchise volume increases of 12%, led by Imbruvica and Darzalex, while immunology products advanced 6% on Stelara and Tremfya demand. Medical device revenue climbed 4.5%, anchored by knee and hip replacements, and vision care products posted a 3.9% rise. Consumer health revenues were flat, reflecting portfolio streamlining.

Management raised its free cash flow target for full-year 2026 to $21 billion, up from prior guidance of $19 billion, reflecting stronger operating margins and disciplined working-capital reductions. The company expects R&D investments of $14 billion to underpin two late-stage oncology filings and three phase-III immunology trials, while capital expenditure remains capped at 4% of sales. At this pace, dividend coverage will exceed 1.5 times, and share repurchases of up to $10 billion are planned, sustaining a return of capital above 50% of net income.

With J&J’s outlook reinforcing sector stability, analysts recommend leaning into diversified healthcare ETFs rather than single-stock exposure. Funds such as the Health Care Select Sector SPDR and iShares U.S. Medical Devices ETF allocate 8–12% to J&J, balancing its solid cash flow trajectory against broader device and biotech innovators. Historical sector volatility has averaged 12% annualized, versus 18% for the S&P 500, suggesting that ETF vehicles may offer investors a smoother participation in J&J’s growth alongside peers like Medtronic, Pfizer and Abbott Laboratories.